CD161⁺ Treg as a potential biomarker for evaluating disease activity and treatment efficacy in rheumatoid arthritis
Clinical Rheumatology · 2026
DOI: 10.1007/s10067-026-08056-4 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Rheumatology, 2026. Verfasst von Ziyi Song und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Rheumatology and Immunology, Peking University People's Hospital, Beijing, 100044, China. Hauptthemen laut MEDLINE: T-Lymphocytes, Regulatory, NK Cell Lectin-Like Receptor Subfamily B, Arthritis, Rheumatoid. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 23 Literaturangaben. Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
BACKGROUND: CD161⁺ regulatory T cells (Tregs) are involved in rheumatoid arthritis (RA) pathogenesis. This study aimed to investigate the levels of circulating CD161⁺ Tregs in RA patients and to evaluate their associations with clinical features, laboratory indicators, and therapeutic responses. METHODS: A total of 172 RA patients meeting the 2010 ACR/EULAR criteria and 110 age- and sex-matched healthy controls (HCs) were enrolled. The proportion of CD161⁺ Tregs in peripheral blood was quantified by flow cytometry. Correlations between CD161⁺ Treg levels and clinical manifestations, laboratory parameters, and disease activity scores (DAS28) were assessed. Twenty-four RA patients were longitudinally followed to assess post-treatment changes in CD161⁺ Tregs and disease activity. RESULTS: The proportions of CD161⁺ Tregs of the total Treg and CD4⁺ T cell populations were significantly elevated in RA patients compared to HCs (P 5.1) compared to those with moderate/low disease activity (P < 0.05). After treatment, decreased CD161⁺ Treg and disease activity scores were observed (P < 0.05), which were particularly pronounced in the group receiving csDMARDs combined with tocilizumab (an IL-6 inhibitor). However, csDMARDs alone or in combination with JAK inhibitors showed no or only partial efficacy. CONCLUSION: CD161⁺ Tregs are elevated in RA and associated with disease activity and immunologic indicators. CD161⁺ Tregs might serve as a biomarker for assessing RA disease activity. Key Points • The proportion of circulating CD161⁺ regulatory T cells is significantly increased in rheumatoid arthritis patients compared to healthy controls. • Higher CD161⁺ Treg levels correlate positively with disease activity scores (DAS28-ESR) and key serological markers (RF, IgA, IgM). • CD161⁺ Treg levels decreased significantly following effective therapy, paralleling reductions in disease activity, particularly in the group receiving csDMARDs combined with tocilizumab. • CD161⁺ Tregs show positive correlations with pro-inflammatory cells (TNF-α+CD4+T cell, Th17) and peripheral T follicular helper cells, underscoring their role in RA immunopathology.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Rheumatology and Immunology, Peking University People's Hospital, Beijing, 100044, China.
- Beijing Key Laboratory of Non-invasive Diagnosis and Immunotherapy of Rheumatic Diseases, Beijing, 100044, China.
- Department of Thoracic Surgery, Peking University People's Hospital, Beijing, 100044, China.
- Thoracic Oncology Institute & Research Unit of Intelligence Diagnosis and Treatment in Early Non-Small Cell Lung Cancer, Peking University People's Hospital, Beijing, China.
- Department of Rheumatology, Allergy and Immunology, Tan Tock Seng Hospital, Jln Tan Tock Seng, Singapore, 308433, Singapore.
- Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore, 308232, Singapore.
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Song, Z., Zhu, D., Sun, F., Geng, J., Xu, C., Jiang, J., Zhang, W., Sun, X., & Li, Z. (2026). CD161⁺ Treg as a potential biomarker for evaluating disease activity and treatment efficacy in rheumatoid arthritis. Clinical Rheumatology. https://doi.org/10.1007/s10067-026-08056-4
Vancouver
Song Z, Zhu D, Sun F, Geng J, Xu C, Jiang J, et al. CD161⁺ Treg as a potential biomarker for evaluating disease activity and treatment efficacy in rheumatoid arthritis. Clinical Rheumatology. 2026. doi:10.1007/s10067-026-08056-4
BibTeX
@article{Song2026,
author = {Song, Ziyi and Zhu, Danxue and Sun, Feng and Geng, Jiayi and Xu, Chuanhui and Jiang, Junyi and Zhang, Wenjuan and Sun, Xiaolin and Li, Zhanguo},
title = {CD161⁺ Treg as a potential biomarker for evaluating disease activity and treatment efficacy in rheumatoid arthritis},
journal = {Clinical Rheumatology},
year = {2026},
doi = {10.1007/s10067-026-08056-4}
}
EUVIMED